PisantiS, MalfitanoAM, CiagliaE, et al.: Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther, 2017; 175:133–150.
2.
RongC, LeeY, CarmonaNE, et al.: Cannabidiol in medical marijuana: Research vistas and potential opportunities. Pharmacol Res, 2017; 121:213–218.
3.
PowellD, PaculaRL, JacobsonM: Do medical marijuana laws reduce addictions and deaths related to pain killers?. J Health Econ, 2018; 58:29–42.
4.
BachhuberMA, SalonerB, CuninghamCO, BarryCL: Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Intern Med, 2014; 174:1668–1673.
5.
RussoEB: Cannabidiol claims and misconceptions. Trends Pharmacol Sci, 2017; 38:499.
6.
MückeM, PhillipsT, RadbruchL, et al.: Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev, 2018; 3:CD012182.
7.
MeadA: The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav, 2017; 70(Pt B):288–291.
8.
WhitingPF, WolffRF, DeshpandeS, et al.: Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 2015; 313:2456–2473.
9.
IfflandK, GrotenhermenF: An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res, 2017; 2:139–154.
10.
WardSJ, McAllisterSD, KawamuraR, et al.: Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol, 2014; 171:636–645.
11.
HammellDC, ZhangLP, MaF, et al.: Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain, 2016; 20:936–948.
12.
CuñettiL, ManzoL, PeyraubeR, et al.: Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay. Transplant Proc, 2018; 50:461–464.
13.
HäuserW, FitzcharlesMA, RadbruchL, PetzkeF: Cannabinoids in pain management and palliative medicine—An overview of systematic reviews and prospective observational studies. Dtsch Arztebl Int, 2017; 114:627–634.
14.
HoggartB, RatcliffeS, EhlerE, et al.: A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. J Neurol, 2015; 262:27–40.
15.
WareMA, WangT, ShapiroS, ColletJP; COMPASS Study Team: Cannabis for the management of pain: Assessment of Safety Study (COMPASS). J Pain, 2015; 16:1233–1242.
16.
HaroutounianS, RatzY, GinosarY, et al.: The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: A prospective open-label study. Clin J Pain, 2016; 32:1036–1043.
17.
ZuardiAW, RodriguesNP, SilvaAL, et al.: Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol, 2017; 8:259.
18.
DevinskyO, CrossJH, LauxL, et al.: Trial of cannabidiol for drug-resistant seizures in the Dravet Syndrome. N Engl J Med, 2017; 376:2011–2020.
19.
CarvalhoRK, SantosML, SouzaMR, et al.: Chronic exposure to cannabidiol induces reproductive toxicity in male Swiss mice. J Appl Toxicol, 2018;2018:38:1215–1223.
20.
StoutSM, CiminoNM: Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review. Drug Metab Rev, 2014; 46:86–95.
21.
HurdYL, YoonM, ManiniAF, et al.: Early phase in the development of cannabidiol as a treatment for addiction: Opioid relapse takes initial center stage. Neurotherapeutics, 2015; 12:807–815.
22.
NielsenS, SabioniP, TrigoJM, et al.: Opioid-sparing effect of cannabinoids: A systematic review and meta-analysis. Neuropsychopharmacology, 2017; 42:1752–1765.
23.
Bonn-MillerMO, LoflinMJE, ThomasBF, et al.: Labeling accuracy of cannabidiol extracts sold online. JAMA, 2017; 318:1708–1709.
